Fibroblast-made GABA fuels PDAC immune suppression
Official title: Role of Fibroblast Glutamate Metabolism in Immunosuppression in Pancreatic Cancer
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11445888 · Data updated 2026-11-12
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $503,896 |
| NIH project number | 1R37CA304810-01A1 |
| Project ID | NIH-11445888 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic ductal adenocarcinoma or those with advanced pancreatic disease may benefit from advances arising from this research.
✕Less likely to help
This research is focused on understanding tumor biology and may not offer immediate treatment options for all patients.
What this research studies
Pancreatic ductal adenocarcinoma (PDAC) often evades the body's immune defenses due in part to cancer-associated fibroblasts shaping an immunosuppressive microenvironment. The project investigates how fibroblast glutamate metabolism leads to the production of GABA, a molecule that can dampen anti-tumor immune cells like NK cells and CD8+ T cells. By studying 3D cell culture systems that mimic the tumor environment, researchers aim to identify targets that block this metabolic pathway without destroying beneficial stromal components. The ultimate goal is to develop stromal-focused therapies that enhance standard treatments and improve patient outcomes. The work combines molecular biology with translational approaches to validate findings in tumor-like conditions that resemble human disease.
Why it matters
Potential benefit: If successful, the research could lead to new strategies that unleash the body's immune response against PDAC and work alongside existing therapies.
How similar studies have gone: Previous work has linked CAF metabolites to immune suppression, and this study extends those findings to a GABA-related mechanism in a 3D model, with prior signals of feasibility but not yet proven in humans.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Francescone, Ralph Anthony — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Francescone, Ralph Anthony
Related research
Other NIH-funded projects on the same topics.
-
Targeting KRAS mutations and immune suppression in pancreatic cancer
This study is looking at how a new treatment for pancreatic cancer that targets a specific mutation can help your immune system fight the tumors better, and it aims to find the best way to combine this treatment with other therapies to improve outcomes for patients like you.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.